SLC5A2 and type 2 diabetes mellitus: Ongoing studies are addressing the role of triple therapy (RAS blockade, SGLT2 inhibition, finerenone) in individuals with T2D and CKD (CONFIDENCE study, NCT05254002) and the efficacy and safety of finerenone in subjects with CKD without diabetes (FIND-CKD study, NCT05047263).